HCC366

302155

GENERAL INFORMATION

Description

HCC366 □□Hamon Cancer Center, UT Southwestern Medical Center□□□□ 80 □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□NSCLC□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ HCC366 □□□□□□□□□□□□□□□DepMap□□CCLE□COSMIC □□□□□ MD Anderson □□□□□□□□□□□□□ □□□□□□□□□ TP53 p.Tyr220Cys □□□DNA □□□□□□□□□□□□□□□ ATM p.Pro534Ala □□□ □□□□□□□ KRAS□EGFR □ STK11 □□□□□□□□□□□□□□□□□□MSS□□□□□□□□ 60–70 □□□
HCC366 □□□□□□□□□NSCLC□□□□□□□□□□□□□□□□□□□□——□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□TP53 □□□□□□□□□□□ ATM □□□ DNA □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ DepMap □ CCLE □□□□□□□□□□□□□□□□□□□□□□□□□□□□NSCLC□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ HCC366 □□□

Tissue	□
Disease	□□□□□□□
Metastatic site	□□□□□□□□□□□□□□□□

Applications

□□□□□□□NSCLC□□□□□□□□□□□□□□□□□TP53 p.Tyr220Cys □□□□□□□□ATM DNA □□□□□□□□□□□□□□□□□□□□□□□□□□□□
DepMap/CCLE □□□□□□□□□□□□□□□□□□□□□□□□□□NSCLC□□□□□□□□□□□□□□□□□□□□

Synonyms

- HCC-366
- HCC0366
- Hamon Cancer Center 366

CLASSIFICATION

Organism	Human
Sex	Female
Growth properties	Adherent
GMO status	Non-GMO

GMO status details

No genetic modification; wildtype NSCLC cell line with endogenous somatic mutations (TP53 p.Tyr220Cys homozygous; ATM p.Pro534Ala heterozygous)

Biosafety level	1

CHARACTERISTICS

Morphology	□□□
Cell type	□□□□
MSI status	MSS
Doubling time	□ 60 □ 70 □□

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

IDENTIFIERS

Citation

HCC366□Cytion □□ 302155□

NCBI TaxID	9606
Cellosaurus	CVCL_2059

EXPRESSION AND SUSCEPTIBILITY

Mutational profile

TP53 p.Tyr220Cys (c.659A>G) □□□□ATM p.Pro534Ala (c.1600C>G) □□□

HANDLING AND CULTURE

Culture medium

RPMI 1640□□ 2.0 mM □□□□□□□□ 2.0 g/L $NaHCO_3$□Cytion □□□□ 820700a□

Incubation atmosphere	37°C□5% CO_2□□□□□□

Supplements

□□□□□□□ 10% □□□□□□□□□

Dissociation reagent	Accutase

Subculturing

□□□□□□□□□□□□□□□□□□□□□□PBS□□□□□T25□□□□□3-5□□PBS□T75□□□□□□5-10□□□ □□□□ Accutase □□□□□□□T25 □□□□□ 1–2 □□□T75 □□□□□□ 2.5 □□□□□□□□□□□□□ 8–10 □□□□□□□□□ □□□□□□□□ 10 □□□□□□□□□□□□□□□□□□□□□ 300xg □□ 3 □□□□□ □□

Split ratio	1 □ 5
Seeding density	1 □ 3 × 10^4 □□□/cm^2
Fluid renewal	□□ 2 □ 3 □
Post-thaw recovery	□□□□□□□□ 5 × 10^4 □□□/cm^2 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ 24 □ □□

Thawing and culturing

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.
Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.
Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

QUALITY CONTROL AND CRYOPRESERVATION

Sterility

□□□□ PCR □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

Freeze medium | 作為冷凍保存培養基，我們使用完全生長培養基（含 FBS）+ 10% DMSO 以確保解凍後的存活率，或使用 CM-1
（Cytion 型號 800100），該培養基含有經優化的滲透保護劑和代謝穩定劑，可提升細胞恢復率並減輕冷凍誘導的壓
力。

Storage conditions
若需長期保存，請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前，可將試管暫時存放於 −80 °C 環境中，作為短期過渡步驟。

Shipping conditions
冷凍保存的細胞系會以乾冰冷藏，並裝於經驗證的隔熱包裝中，包裝內含有足夠的冷媒，以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後，請立即檢查容器，並盡快將試管轉移至適當的儲存場所。

DONOR

Donor age | 80年

Ethnicity | 歐洲的

LEGAL AND SAFETY

Safety precautions
若計劃將低溫試管存放在液態氮中以供日後解凍，必須嚴格遵守相關安全措施。 必須穿戴適當的防護手套和防護服，且在將冷凍樣本移入或移出液氮罐時，必須佩戴口罩或安全護目鏡。此舉旨在降低因取出時冷凍試管可能發生爆炸而導致受傷的風險，此類爆炸可能造成尖銳碎片飛濺。

Warranty
在 Cytion，我們對產品的品質與存活率提供保障。
我們保證，自本公司設施出貨後
60 天內，我們的細胞在培養開始時仍具存活能力。
我們保證所有材料均符合
分析證明書及／或產品說明書中所載的規格。
詳情請參閱我們的
《保固聲明》。

Material Transfer Agreement required | Yes

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

3 / 3